The extent of minimal residual disease reduction after the first 4‐week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome‐positive acute lymphoblastic leukemia
Cancer2009Vol. 115(3), pp. 561–570
Citations Over TimeTop 10% of 2009 papers
Seok Lee, Yoo‐Jin Kim, Nak‐Gyun Chung, Jihyang Lim, Dong‐Gun Lee, Hee‐Je Kim, Chang‐Ki Min, Jong‐Wook Lee, Woo‐Sung Min, Chun‐Choo Kim
Abstract
Prospective assessment of the extent of minimal residual disease reduction after the first 4-week imatinib therapy may allow the authors to identify subgroups of Ph-positive ALL transplants at high risk of relapse.
Related Papers
- → Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis(2013)14 cited
- → Quantitative approaches to analyzing imatinib-treated chronic myeloid leukemia(2007)27 cited
- → Efficacy of imatinib mesylate (STI571) in chronic neutrophilic leukemia with t(15;19): Case report(2004)15 cited
- → Simultaneously occurring chronic myelogenous leukemia and gastrointestinal stromal tumors treated with imatinib(2006)
- Molecular Monitoring of Chronic Myeloid Leukemia Treated with Imatinib Mesylate(2007)